Entries |
Document | Title | Date |
20080227848 | Assays - A method of identifying an agent which modulates 2-oxoglutarate dependent oxygenase activity, the method comprising contacting a 2-oxoglutarate dependent oxygenase and a test agent in the presence of a substrate comprising one or more ankyrin repeat, or fragment thereof, in conditions under which the substrate is hydroxylated in the absence of the test agent; and determining hydroxylation of the substrate. | 09-18-2008 |
20080227849 | Orally Disintegrable Solid Preparation Comprising Povidone-Iodine - An orally disintegratable solid preparation comprising povidone-iodine as an active ingredient, which is obtained by direct powder compression of a mixture containing a granular sugar alcohol and povidone-iodine, wherein the mixture does not contain a basic ingredient and is not subjected to wet granulation. High quality solid preparation as an orally disintegratable preparation comprising povidone-iodine, which have a constant content of povidone-iodine per a single unit solid preparation and maintain stability of iodine, are provided. | 09-18-2008 |
20080242720 | KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT AND ALTERNATING IRRITABLE BOWEL SYNDROME - The present invention concerns methods useful in treating one or more subtypes of irritable bowel syndrome (IBS), or useful in treating diarrhea. The invention relates to the use of peripherally selective kappa-opiate agonists, especially N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof for treating a subject having diarrhea-predominant IBS (IBS-D) or IBS with alternating diarrhea and constipation (IBS-A), or a subject having diarrhea. | 10-02-2008 |
20080255222 | PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES - The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3. | 10-16-2008 |
20080269316 | Pharmaceutical Compositions Comprising Levetiracetam and Process for Their Preparation - The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation. | 10-30-2008 |
20080287522 | BENZYLATED PDE4 INHIBITORS - The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof. | 11-20-2008 |
20080312309 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA - The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present invention are adapted for the treatment and prevention of arrhythmia and other disease or disorders in subjects identified as having altered drug metabolism due to polymorphism of the gene encoding cytochrome P450 2D6. | 12-18-2008 |
20090036514 | Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury - The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke. | 02-05-2009 |
20090036515 | METHOD FOR TREATING COLONIC VISCEROSENSITIVITY AND SPASTICITY - There is provided a method of treating colonic viscerosensitivity and spasticity induced by a colonic examination chosen from colonic endoscopy and of barium/air contrast colonic radiography and virtual colonoscopy. The method comprises prescribing and/or administering to a patient in need thereof a pharmaceutically effective oral, sub-lingual, nasal or transdermic dose of a non-centrally-acting opioid agonist for a period of at least two days before the colonic examination. | 02-05-2009 |
20090048329 | Substituted Pyrrolidine Compounds With Central Nervous System Activity - Provided herein are substituted pyrrolidines that demonstrate binding at biogenic amine transporters and can be synthesized by a methodology based on a chiral dirhodium catalyst. Compositions comprising substituted pyrrolidines can be used to treat central nervous system disorders such as schizophrenia. | 02-19-2009 |
20090062372 | Glycopyrronium Salts and Their Therapeutic Use - A glycopyrronium salt such as glycopyrronium iodide has a lower glass transition temperature than glycopyrronium bromide. It is therefore more suitable for formulation. | 03-05-2009 |
20090069404 | DEUTERIUM-ENRICHED VERNAKALANT - The present application describes deuterium-enriched vemakalant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090082422 | DEUTERIUM-ENRICHED LEVETIRACETAM - The present application describes deuterium-enriched levetiracetam, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-26-2009 |
20090088464 | Merged ion channel modulating compounds and Uses Thereof - Merged compounds of ion channel modulating compounds, including, for example, merged compounds of the ion channel modulating compound of the following formula: (I) are described herein, as well as methods of making and using such merged compounds and pharmaceutical compositions containing such merged compounds. | 04-02-2009 |
20090131508 | Use of 2-Oxo-1-Pyrrolidone Derivatives for the Preparation of a Drug - The present invention relates to the use of brivaracetam for the preparation of drugs effective for the prevention or treatment of progressive myoclonic epilepsies. | 05-21-2009 |
20090215857 | Therapeutic Pyrrolidines - The present invention provides for compounds of Formula (I), | 08-27-2009 |
20090270478 | ION CHANNEL MODULATING ACTIVITY II - Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g., atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes. | 10-29-2009 |
20090291999 | Agent Exhibiting a Neurotropic, Neuromodulator, Cerebrovascular and Anti-Stroke Activity - The invention relates to medicine, in particular to pharmacology and to medicinal agents exhibiting a neurotropic and cerebrovascular activity. The novelty of the invention consists in that an N-carbomoyl-methyl-4-phenyl-2-pyrrolidon agent injected into an organism displays an universal pronounced effect in the form of the one hundred percent survival of animals, eliminates the development of a neurological symptom complex of a cerebral stroke of different aetiologies, localizes a cerebral affection area and the destructive development thereof. It is proved, that the inventive agent exhibits universal neurotropic (neuromodulator) activity and produces a neuroprotective-cerebrovascular action. | 11-26-2009 |
20090298908 | DMAE AS SOLE AGENT FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT - The present invention relates to the use, as sole active ingredient, of dimethylaminoethanol (DMAE) in free form or in the form of salts or of esters and also of hydrates and solvates thereof, for the manufacture of a medicament for use in the treatment of a non-dementia mild cognitive impairment characterized by an amnestic syndrome of hippocampal type. | 12-03-2009 |
20100029744 | Methods for Alzheimer's Disease Treatment and Cognitive Enhancement - The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition. | 02-04-2010 |
20100048665 | 3-AMINOPYRROLIDONE DERIVATIVES - 3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases. | 02-25-2010 |
20100056603 | ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local anesthesia. | 03-04-2010 |
20100056604 | METHODS FOR STIMULATING NERVOUS SYSTEM REGENERATION AND REPAIR BY INHIBITING PHOSPHODIESTERASE TYPE IV - The invention relates to the novel identification of inhibitors of phosphodiesterase type 4 (“PDE4”) as agents which can reverse inhibition of neural regeneration in the mammalian central and peripheral nervous system. The invention provides compositions and methods using agents that can reverse the inhibitory effects on neural regeneration by regulating PDE4 expression. A composition comprising at least one PDE4 inhibitor in an amount effective to inhibit PDE4 activity in a neuron when administered to an animal is provided. Methods for regulating (e.g., promoting) neural growth or regeneration in the nervous system, methods for treating injuries or damage to nervous tissue or neurons, and methods for treating neural degeneration associated with disorders or diseases, comprising the step of administering to an animal a composition comprising a therapeutically effective amount of an agent which inhibits phosphodiesterase IV activity in a neuron are provided. | 03-04-2010 |
20100087506 | CYCLIC AMINE COMPOUND - Provision of a compound having a superior androgen receptor regulating action. | 04-08-2010 |
20100120890 | ION CHANNEL MODULATING ACTIVITY I - Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, early afterdepolarizations and prolongation of QT interval may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes. | 05-13-2010 |
20100152276 | DEUTERATED AMINOCYCLOHEXYL ETHER COMPOUNDS AND PROCESSES FOR PREPARING SAME - This invention is directed to deuterated aminocyclohexyl ether compounds and processes for preparing same and methods of using same. | 06-17-2010 |
20100210706 | PYRROLIDINONE ANILINES AS PROGESTERONE RECEPTOR MODULATORS - The present invention relates to a compound represented by the following formula: | 08-19-2010 |
20100240728 | Co-Crystals of Pyrrolidinones - The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R | 09-23-2010 |
20100292296 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 11-18-2010 |
20110118329 | USES OF ION CHANNEL MODULATING COMPOUNDS - Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. | 05-19-2011 |
20110178152 | COMPOSITION COMPRISING S-ALLYLMERCAPTO-N-ACETYLCYSTEINE (ASSNAC) FOR UP-REGULATION OF CELLULAR GLUTATHIONE LEVEL - The present invention relates to S-allylmercapto-N-acetylcysteine (ASSNAC) and its pharmaceutically acceptable salts and solvates, which are useful for up-regulation of cellular glutathione levels and expression of phase II detoxifying enzymes. The invention further provides methods of use thereof in the prevention, alleviation or treatment of oxidative stress induced by reactive oxygen species (ROS). | 07-21-2011 |
20110201665 | Compositions, Methods, and Kits for Treating Influenza Viral Infections - The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infection caused by an influenza virus). | 08-18-2011 |
20110207794 | PHARMACEUTICAL COMPOSITION - The present invention relates to an oral controlled release pharmaceutical composition in the form of a unit dosage form comprising:
| 08-25-2011 |
20110257241 | 3-PHENYL-3-METHOXYPYRROLIDINE DERIVATIVES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION - The present invention relates to novel 3-phenyl-3-methoxy-pyrrolidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-3-methoxy-pyrrolidine derivatives of the invention and to the use of these compounds for therapeutic applications. | 10-20-2011 |
20110275693 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-10-2011 |
20110281929 | Pharmaceutical Compositions Comprising 2-Oxo-1-Pyrrolidine Derivatives - The present invention relates to an immediate release formulation of pharmaceutical compounds. | 11-17-2011 |
20110306649 | PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF - Prodrugs of ion channeling modulating compounds, including, for example, prodrugs of the ion channel modulating compound of the following formula: | 12-15-2011 |
20110306650 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE - The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications. | 12-15-2011 |
20120022127 | PROCESS FOR PREPARING PYRROLIDINIUM SALTS - A two step process for preparing a compound of formula I | 01-26-2012 |
20120035239 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES - The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, | 02-09-2012 |
20120046336 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI). | 02-23-2012 |
20120095073 | ION CHANNEL MODULATING ACTIVITY II - Methods, compositions, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early afterdepolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds. Also described are compositions of ion channel modulating compounds and drugs which induce early afterdepolarizations, prolongation of QT interval and/or Torsades de Pointes. | 04-19-2012 |
20120101145 | Oligomer-Containing Pyrrolidine Compounds - The invention relates to (among other things) oligomer-containing pyrrolidine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 04-26-2012 |
20120214859 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to methods and compositions for treating central nervous system (CNS) disorders with cognitive impairment. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating central nervous system (CNS) disorders with cognitive impairment in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, amyotrophic lateral sclerosis and cancer-therapy-related cognitive impairment. | 08-23-2012 |
20120238614 | ANTICONVULSANT COMBINATION THERAPY - The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures. | 09-20-2012 |
20120245215 | Co-Crystals of Pyrrolidinones - The present invention relates to new co-crystals of pyrrolidinones having the formula (I) wherein R | 09-27-2012 |
20120258996 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS - Novel ligand compounds having the general formula (I): | 10-11-2012 |
20130065936 | MODULATION OF BIOACTIVE EPOXY-FATTY ACID LEVELS BY PHOSPHODIESTERASE INHIBITORS - The present invention provides method for increasing levels of epoxygenated fatty acids by administration of a phosphodiesterase inhibitor. | 03-14-2013 |
20130172398 | Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases - A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed. | 07-04-2013 |
20130237583 | PROCESS FOR THE PREPARATION OF DIHYDROPYRROLE DERIVATIVES - The present invention provides stereoselective processes for the preparation of compounds of formula (I) wherein P is phenyl, naphthyl, a 6-membered heteroaryl group containing one or two nitrogen atoms as ring members, or a 10-membered bicyclic heteroaryl group containing one or two nitrogen atoms as ring members, and wherein the phenyl, naphthyl and heteroaryl groups are optionally substituted; R | 09-12-2013 |
20130331428 | TOPICAL COMPOSITIONS CONTAINING A RETINOID OF THE OIL-IN-WATER EMULSION TYPE - A composition in the form of an oil in water emulsion, preferably without emulsifier, is described. The composition can include, in a physiologically acceptable environment, at least one new retinoid. Also described, is the method of preparing the composition and its use in cosmetics and dermatology. | 12-12-2013 |
20140018406 | Treatment of Chronic Obstructive Pulmonary Disease With Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration - Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The inhalation solutions are administered by nebulization, particularly with a high efficiency nebulizer. | 01-16-2014 |
20140080890 | USE OF GLYCOPYRROLATE FOR TREATING TACHYCARDIA - The invention relates to a novel use of the antimuscarinic agent glycopyrrolate, for example the salt glycopyrronium bromide. In particular, the invention relates to glycopyrrolate for use as a heart rate lowering agent and more particularly, but not exclusively, for use in patients suffering from respiratory conditions such as chronic obstructive pulmonary disease. | 03-20-2014 |
20140088168 | ANTICONVULSANT COMBINATION THERAPY - The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures. | 03-27-2014 |
20140275204 | METHOD OF DOSING AND USE OF SOFT ANTICHOLINERGIC ESTERS - A method of treating hyperhidrosis in a mammalian subject comprising:
| 09-18-2014 |
20140296317 | 4R,5S-ENANTIOMER OF 2-(5-METHYL-2-OXO-4-PHENYL-PYRROLIDIN-1-YL)-ACETAMIDE WITH NOOTROPIC ACTIVITY - The invention relates to the 5S,4R-enantiomer of 2-(5-methyl-2-oxo-4-phenyl-pyrrolidin-1-yl)-acetamide with cognition enhancing activity of high pharmacological value and to its preparation method which includes the synthesis of 5S-methyl-4R-phenylpyrrolidin-2-one, its N-alkylation with ethyl haloacetate and the treatment of intermediate ethyl 2-(5S-methyl-2-oxo-4R-phenyl-pyrrolidin-1-yl)-acetate with ammonia. | 10-02-2014 |
20140315972 | RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide compound having modulatory activity with a commensurate effect, pharmaceutical substance (variants) and its application, composition (variants) thereof - The invention relates to a compound (RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide having modulatory activity with a commensurate effect, to a pharmaceutical substance (RS)-2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide containing: 2-(2-oxo-4-phenylpyrrolidin-1-yl)acetamide—no less than 99.0% and no more than 100.5% on dry basis, individual related impurities individually or in total—no more than 0.2%; residual amounts of organic solvents individually or in total—no more than 3000 ppm. The invention also relates to a method for producing the pharmaceutical substance differing in that the obtained raw materials are subjected to purification, crystallization and stabilization of the compound by processing it with demineralized (distilled) water, and the isothermal crystallization from propanol followed by drying. The invention also relates to compositions for internal and external application. The invention provides higher efficacy, safety, stability and width of therapeutic application. 55 cl, 3 dwg, 80 tbl, 27 ex. | 10-23-2014 |
20140364479 | PROCESS FOR THE PREPARATION OF GLYCOPYRRONIUM CHLORIDE - The invention concerns a method for preparing glycopyrronium chloride, and its use in pharmaceutical applications. | 12-11-2014 |
20140371290 | Glycopyrrolate Salts - Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed. | 12-18-2014 |
20150094352 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to treating age-related cognitive impairment. This invention in particular relates to the use of inhibitors of synaptic vesicle protein 2A (SV2A), such as levetiracetam, seletracetam, and brivaracetam, in improving cognitive function in subjects that exhibit age-related cognitive impairment or are at risk thereof, including, without limitation, subjects having or at risk for Mild Cognitive Impairment (MCI), Age-related Cognitive Decline (ARCD) or Age-Associated Memory Impairment (AAMI). | 04-02-2015 |
20150094353 | Inhibitors Targeting the DNA-Binding Domain of Human STAT3 for Treatment of Metastatic Cancers - The present invention provides STAT3 inhibitors which preferentially suppress proliferation of cancer over non-cancer cells and inhibit migration and invasion of malignant cells. The inhibitors of the present invention selectively inhibit STAT3 binding to DNA without affecting the activation and dimerization of STAT3. Furthermore, the inhibitors of the present invention inhibit expression of STAT3 downstream target genes and STAT3 binding to chromatin in situ. | 04-02-2015 |
20150099788 | CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA - The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present invention are adapted for the treatment and prevention of arrhythmia and other disease or disorders in subjects identified as having altered drug metabolism due to polymorphism of the gene encoding cytochrome P450 2D6. | 04-09-2015 |
20150126576 | NEURONAL PAIN PATHWAY MODULATORS - The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol. | 05-07-2015 |
20150141481 | Treatment of Chronic Obstructive Pulmonary Disease with Nebulized Beta 2-Agonist or Combined Nebulized Beta 2-Agonist and Anticholinergic Administration - Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The inhalation solutions are administered by nebulization, particularly with a high efficiency nebulizer. | 05-21-2015 |
20150307449 | PYRROLE SULFONAMIDE DERIVATIVE, PREPARATION METHOD FOR SAME, AND MEDICAL APPLICATION THEREOF - The present invention relates to a pyrrole sulfonamide derivative, a preparation method for the same, and medical applications thereof. Specifically, the present invention relates to a novel pyrrole sulfonamide derivative as represented by formula (I), a preparation method for the derivative, a pharmaceutical composition comprising the derivative, and uses of the same as therapeutic agents, and particularly as gastric acid secretion inhibitors and potassium-competitive acid blockers (P-CABs), wherein each substituent of formula (I) is as defined in the description. | 10-29-2015 |
20150320722 | FORMULATION FOR SOFT ANTICHOLINERGIC ANALOGS - Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis. | 11-12-2015 |
20150344413 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present application relates to novel compounds comprising a moiety that leads to the metabolic production of ketones bonded to a ketone-potentiated anti-epileptic drug, compositions comprising these compounds, and their use, for example for the treatment of epilepsy, and other CNS diseases, disorders or conditions. In particular, the present application includes compounds of Formula I, and compositions and uses thereof: | 12-03-2015 |
20150352077 | Multi-Component Crystalline Particles for Inhalation Therapy - Pharmaceutical Preparations Multi-component crystalline particles and compositions, methods for their preparation, their uses in inhalation therapy and inhaler devices containing said particles are provided, in particular particles comprising glycopyrrolate. The particles can be prepared substantially free of excipients and agents other than active agents or their precursors in the presence of ultrasonic irradiation in a process comprising contacting a solution in a first flowing stream with an anti-solvent in a re-circulating second flowing stream, causing the mixing thereof and collecting crystals that are generated. | 12-10-2015 |
20150366842 | OLIGOMER-CONTAINING PYRROLIDINE COMPOUNDS - The invention relates to (among other things) oligomer-containing pyrrolidine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer. | 12-24-2015 |
20150374621 | USE OF SELECTED ANTICHOLINERGIC ZWITTERIONS - Selected anticholinergic zwitterions are administered to slow the progression of myopia in children and to treat myopia generally. | 12-31-2015 |
20160030391 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A) in combination with memantine or a derivative or an analog thereof, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age-Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia or bipolar disorder, amyotrophic lateral sclerosis, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction. | 02-04-2016 |
20160038463 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION - This invention relates to methods and compositions for treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of inhibitors of synaptic vesicle glycoprotein 2A (SV2A), alone or in combination with valproate, in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment. | 02-11-2016 |
20160046574 | SEROTONIN RECEPTOR MODULATORS - Certain biphenyic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 02-18-2016 |
20160067214 | METHOD OF DOSING AND USE OF SOFT ANTICHOLINERGIC ESTERS - A method of treating hyperhidrosis in a mammalian subject comprising:
| 03-10-2016 |
20160073631 | PROCESS FOR THE PREPARATION OF DIHYDROPYRROLE DERIVATIVES - The present invention provides stereoselective processes for the preparation of compounds of formula (I) | 03-17-2016 |
20160113902 | Glycopyrrolate Salts - Salts of glycopyrrolate, including solid forms and formulations such as topicals thereof, are disclosed. Methods of making glycopyrrolate salts, including formulations such as topicals thereof, and methods of treating hyperhidrosis with salts of glycopyrrolate, and formulations such as topicals thereof, are disclosed. | 04-28-2016 |
20160374987 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH NEBULIZED BETA 2-AGONIST OR COMBINED NEBULIZED BETA 2-AGONIST AND ANTICHOLINERGIC ADMINISTRATION - Inhalation solutions for administration of beta 2-agonists or combinations of muscarinic antagonists and beta 2-agonists for the treatment of breathing disorders, such as COPD, are provided. The inhalation solutions are administered by nebulization, particularly with a high efficiency nebulizer. | 12-29-2016 |
20190144384 | Chemical Compounds | 05-16-2019 |
20190144407 | Synthetic Ligands that Modulate the Activity of the RhlR Quorum Sensing Receptor | 05-16-2019 |